GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Elevation Oncology Inc (NAS:ELEV) » Definitions » FCF Yield %

Elevation Oncology (Elevation Oncology) FCF Yield % : -27.30 (As of May. 11, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Elevation Oncology FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Elevation Oncology's Trailing 12-Month Free Cash Flow is $-48.92 Mil, and Market Cap is $179.21 Mil. Therefore, Elevation Oncology's FCF Yield % for today is -27.30%.

The historical rank and industry rank for Elevation Oncology's FCF Yield % or its related term are showing as below:

ELEV' s FCF Yield % Range Over the Past 10 Years
Min: -509.25   Med: 0   Max: 0
Current: -27.3


ELEV's FCF Yield % is ranked worse than
63.24% of 1556 companies
in the Biotechnology industry
Industry Median: -14.17 vs ELEV: -27.30

Elevation Oncology's FCF Margin % for the quarter that ended in Mar. 2024 was 0.00%.


Elevation Oncology FCF Yield % Historical Data

The historical data trend for Elevation Oncology's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elevation Oncology FCF Yield % Chart

Elevation Oncology Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
FCF Yield %
- - -21.59 -386.37 -246.61

Elevation Oncology Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -148.97 -85.76 -190.11 -213.88 -14.45

Competitive Comparison of Elevation Oncology's FCF Yield %

For the Biotechnology subindustry, Elevation Oncology's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Elevation Oncology's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Elevation Oncology's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Elevation Oncology's FCF Yield % falls into.



Elevation Oncology FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Elevation Oncology's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-56.18 / 22.7808825
=-246.61%

Elevation Oncology's annualized FCF Yield % for the quarter that ended in Mar. 2024 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-9.575 * 4 / 265.115322
=-14.45%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Elevation Oncology FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Elevation Oncology FCF Yield % Related Terms

Thank you for viewing the detailed overview of Elevation Oncology's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Elevation Oncology (Elevation Oncology) Business Description

Traded in Other Exchanges
N/A
Address
888 Seventh Avenue, 12th Floor, New York, NY, USA, 10106
Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.
Executives
Tammy Furlong officer: CHIEF FINANCIAL OFFICER C/O ELEVATION ONCOLOGY, INC., 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Venbio Global Strategic Gp Iii, L.p. 10 percent owner 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Venbio Global Strategic Fund Iii, L.p. 10 percent owner 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Goodman Corey S 10 percent owner 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Robert J Adelman 10 percent owner 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Aaron Royston 10 percent owner 200 CARDINAL WAY, 2ND FLOOR, REDWOOD CITY CA 94063
David Dornan officer: Chief Scientific Officer C/O BOLT BIOTHERAPEUTICS, INC., 640 GALVESTON DRIVE, REDWOOD CITY CA 94063
Valerie Malyvanh Jansen officer: Chief Medical Officer C/O ELEVATION ONCOLOGY, INC., 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Andrew N Schiff other: Managing Member PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022
Steve Elms director, other: Managing Member 888 SEVENTH AVE, 29TH FL, NEW YORK NY 10106
Venbio Global Strategic Gp Iii, Ltd 10 percent owner 1700 OWENS STREET, SUITE 595, SAN FRANCISCI CA 94158
Qiming U.s. Healthcare Gp Ii, Llc 10 percent owner 11100 NE 8TH ST, SUITE 200, BELLEVUE WA 98004
Vertex Global Hc Fund Ii Pte. Ltd. 10 percent owner 250 NORTH BRIDGE ROAD, #11-01 RAFFLES CITY TOWER, SINGAPORE U0 179101
Walsh Colin director C/O ELEVATION ONCOLOGY, INC., 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106